Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, +239

The Lancet

Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment +4

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski, +16

The Lancet

Non-small-cell Lung CancerMedicineCancer ManagementClinical TrialsCancer Treatment +4

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han, +29

New England Journal of Medicine

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, +247

The Lancet Oncology

Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment +4

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, +14

Journal of Clinical Oncology

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, +14

The Lancet Oncology

OncologyCancer ManagementMaintenance TherapyCancer TreatmentMedicine +3

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, +148

The Lancet Oncology

MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment +3

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park, +164

Annals of Oncology

Expression of CEACAM1 in Adenocarcinoma of the Lung: A Factor of Independent Prognostic Significance

Eckart Laack, Haleh Nikbakht, Anja Peters, +6

Journal of Clinical Oncology

Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study

Tudor–Eliade Ciuleanu, T. Brodowicz, Chandra P. Belani, +7

Journal of Clinical Oncology

Family MedicineCancer ManagementPharmacotherapyPre-clinical PharmacologyOncology +17